Bayer AG divests plasma unit
This article was originally published in The Gray Sheet
Executive Summary
German firm's restructuring to focus on high-performance diagnostic systems, consumer health and pharmaceuticals includes divestiture of plasma business, which makes drugs. Newly formed NPS BioTherapeutics, backed by Cerberus Capital and Ampersand Ventures, will buy the unit for $590 mil. under a Dec. 13 deal...